Long-Term Treatment With a Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Intestinal Tumors in Models of Diabetes and Obesity

被引：0
|
作者：
Fujiwara, Kaori
Yorifuji, Naoki
Nouda, Sadaharu
Kakimoto, Kazuki
Okada, Toshihiko
Kawakami, Ken
Takeuchi, Toshihisa
Inoue, Takuya
Higuchi, Kazuhide
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)32025-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1926
引用
收藏
页码：S591 / S591
页数：1
相关论文
共 50 条
  • [1] Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Odawara M.
    Kadowaki T.
    Tajima N.
    Nishii M.
    Taniguchi T.
    Ferreira J.C.A.
    Diabetology International, 2011, 2 (2) : 94 - 105
  • [2] The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice
    Yorifuji, Naoki
    Inoue, Takuya
    Fujiwara, Kaori
    Iguchi, Munetaka
    Kojima, Yuichi
    Okada, Toshihiko
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S577 - S577
  • [3] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
  • [4] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339
  • [5] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [6] The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice
    Al Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Manoj, Priyadarsini
    Ashique, Mohammed
    Nemmar, Abderrahim
    Ali, Badreldin H.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 : 1102 - 1108
  • [7] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [8] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [9] The Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Gentamicin Nephrotoxicity in Mice
    Ali, Badreldin H.
    Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Nemmar, Abderrahim
    FASEB JOURNAL, 2018, 32 (01):
  • [10] The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
    Kubota, Yoshiaki
    Miyamoto, Masaaki
    Takagi, Gen
    Ikeda, Takeshi
    Kirinoki-Ichikawa, Sonoko
    Tanaka, Kotoko
    Mizuno, Kyoichi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (11) : 1364 - 1370
12345